The research publication of the in vivo genome editing project for congenital muscular dystrophy in T-CiRA Joint Program were published online in Nature Communications on December 8th 2021.

The research publication of the in vivo genome editing project for congenital muscular dystrophy in T-CiRA Joint Program (Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice)
were published online in Nature Communications on December 8^th 2021.
doi: 10.1038/s41467-021-26714-w

Paper Details

Journal: Nature Communications
Title: Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice doi: 10.1038/s41467-021-26714-w
Authors: Eriya Kenjo1,2, Hiroyuki Hozumi1,2, Yukimasa Makita1,2, Kumiko A. Iwabuchi2,3, Naoko Fujimoto2,3, Satoru Matsumoto1,2, Maya Kimura1, Yuichiro Amano1, Masataka Ifuku2,3, Youichi Naoe2,3, Naoto Inukai1,2, and Akitsu Hotta2,3
Author Affiliations:

1 T-CiRA Discovery, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
2 Takeda-CiRA Joint Program (T-CiRA), Kanagawa, Japan
3 Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan